Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation

5 de agosto de 2016 actualizado por: Gilead Sciences

A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 48 Weeks in Patients Infected With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation

This study will evaluate the antiviral efficacy of combination therapy with sofosbuvir (SOF) plus ribavirin (RBV) for 48 weeks in adults with compensated and decompensated chronic hepatitis C virus (HCV) infection. Approximately 50 adults will be randomized (1:1) to receive study drug for 48 weeks or take part in an untreated observational arm for the first 24 weeks followed by study drug for another 48 weeks.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Actual)

50

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • New South Wales
      • Newtown, New South Wales, Australia
      • Barcelona, España
    • Madrid
      • Majadahonda, Madrid, España
    • Colorado
      • Aurora, Colorado, Estados Unidos
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos
    • Minnesota
      • Rochester, Minnesota, Estados Unidos
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos
    • Clichy
      • Leclerc, Clichy, Francia
    • Auckland
      • Grafton, Auckland, Nueva Zelanda

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Chronic infection with Hepatitis C with HCV RNA > 1000 IU/mL
  • Individuals with cirrhosis with Child-Pugh score < 10
  • Esophageal or gastric varices on endoscopy within 6 months prior to or at screening
  • Hepatic Venous Pressure Gradient (HVPG) > 6 mmHg
  • Body mass index (BMI) ≥ 18 kg/m^2
  • Naïve to all nucleotides/nucleoside treatments for chronic HCV infection

Exclusion Criteria:

  • Have any serious or active medical or psychiatric illness which, in the opinion of the investigator, would interfere with subject treatment, assessment, or compliance
  • HIV or chronic hepatitis B virus (HBV) infection (HBsAg positive)
  • Alpha-fetoprotein (AFP) > 50 unless negative imaging for hepatic masses within the last 6 months or during screening
  • Refractory ascites as defined by requiring paracentesis > twice within 1 month prior to screening
  • Active variceal bleeding within 6 months of screening
  • Expected survival of < 1 year
  • History of hepatorenal, or hepatopulmonary syndrome.
  • Evidence of renal impairment (CrCl < 50 mL/min)
  • History of major organ transplantation, including liver transplant.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: SOF+RBV
Participants will receive SOF+RBV for 48 weeks.
Comprimidos de RBV administrados por vía oral en una dosis diaria dividida de acuerdo con las recomendaciones de dosificación basadas en el peso del prospecto (< 75 kg = 1000 mg y ≥ 75 kg = 1200 mg)
SOF 400 mg comprimido administrado por vía oral una vez al día
Otros nombres:
  • Sovaldi®
  • GS-7977
Experimental: Observation, then SOF+RBV
Participants will undergo 24 weeks of observation and then receive SOF+RBV for 48 additional weeks.
Comprimidos de RBV administrados por vía oral en una dosis diaria dividida de acuerdo con las recomendaciones de dosificación basadas en el peso del prospecto (< 75 kg = 1000 mg y ≥ 75 kg = 1200 mg)
SOF 400 mg comprimido administrado por vía oral una vez al día
Otros nombres:
  • Sovaldi®
  • GS-7977

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
Periodo de tiempo: Posttreatment Week 12 (SOF+RBV) and up to 24 weeks (Observation)
SVR12 was defined as HCV RNA < the lower limit of quantitation (LLOQ; ie, 25 IU/mL) at 12 weeks after stopping study treatment. For the Observation/SOF+RBV group, SVR12 during the observational period was defined as HCV RNA < LLOQ for 12 consecutive weeks, any time during the observational period.
Posttreatment Week 12 (SOF+RBV) and up to 24 weeks (Observation)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of Participants With SVR at 4, 24, and 48 Weeks After Discontinuation of Therapy (SVR4, SVR24, and SVR48)
Periodo de tiempo: Posttreatment Weeks 4, 24, and 48
SVR4, SVR24, and SVR48 were defined as HCV RNA < LLOQ at 4, 24, and 48 weeks after stopping study treatment, respectively.
Posttreatment Weeks 4, 24, and 48
Percentage of Participants Experiencing On-Treatment Virologic Failure
Periodo de tiempo: Up to 48 weeks

On-treatment virologic failure was defined as:

  • Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA < LLOQ while on treatment), or
  • Rebound (confirmed > 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or
  • Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)
Up to 48 weeks
Percentage of Participants Experiencing Viral Relapse
Periodo de tiempo: Up to Posttreatment Week 24
Viral relapse was defined as HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA < LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement.
Up to Posttreatment Week 24
Change From Baseline in Hepatic Venous Pressure Gradient (HVPG) at End of Treatment
Periodo de tiempo: Baseline; Week 24 (Observation) and Week 48 (SOF+RBV)
HVPG closely reflects the degree of portal hypertension in patients with cirrhosis. The end of treatment for the Observation group was defined as the end of the observation period. The treatment period for Group 2 was defined as the end of the observation period to the end of the treatment. Baseline values were the last available values on or prior to first dose date of any study drug.
Baseline; Week 24 (Observation) and Week 48 (SOF+RBV)
Change From Baseline in Child-Pugh-Turcotte (CPT) Score
Periodo de tiempo: Baseline; Week 24 (Observation) and Posttreatment Week 4 (SOF+RBV)

CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease. Data are presented as improvement, no change, or worsening in CPT scores at Week 24 (Observation) and Posttreatment Week 4 (SOF+RBV groups).

Improvement in CPT score was defined as having a decrease in CPT score from baseline, no change in CPT score was defined as having no change in CPT score from baseline, and worsening in CPT score was defined as having an increase in CPT score from baseline.

Baseline values were the last available values on or prior to first dose date of any study drug.

Baseline; Week 24 (Observation) and Posttreatment Week 4 (SOF+RBV)
Change From Baseline in Model for End Stage Liver Disease (MELD) Scores
Periodo de tiempo: Baseline; Week 24 (Observation) and Posttreatment Week 4 (SOF+RBV)

MELD scores, used to assess prognosis and suitability for transplant, are calculated based on laboratory values only and can range from 6 to 40, with higher scores indicating greater disease severity. Data are presented as improvement, no change, or worsening in MELD scores at Week 24 (Observation) and Posttreatment Week 4 (SOF+RBV groups).

Improvement in MELD score was defined as having a baseline MELD score of 11-15 or 16-20 that changed to 0-10, or a baseline MELD score of 16-20 that changed to 11-15; no change in MELD score was defined as having no change in score group (0-10, 11-15, or 16-20) from baseline; and worsening in MELD score was defined as having a baseline MELD score of 0-10 that changed to 11-15 or 16-20, or a baseline MELD score of 11-15 that changed to 16-20.

Baseline values were the last available values on or prior to first dose date of any study drug.

Baseline; Week 24 (Observation) and Posttreatment Week 4 (SOF+RBV)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio

1 de julio de 2012

Finalización primaria (Actual)

1 de enero de 2015

Finalización del estudio (Actual)

1 de octubre de 2015

Fechas de registro del estudio

Enviado por primera vez

12 de septiembre de 2012

Primero enviado que cumplió con los criterios de control de calidad

13 de septiembre de 2012

Publicado por primera vez (Estimar)

18 de septiembre de 2012

Actualizaciones de registros de estudio

Última actualización publicada (Estimar)

16 de septiembre de 2016

Última actualización enviada que cumplió con los criterios de control de calidad

5 de agosto de 2016

Última verificación

1 de agosto de 2016

Más información

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir